IMMULITE 2000 XPI ANTI-HBC IMG

Test, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)

FDA Premarket Approval P010053

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the immulite anti-hbc igm and immulite 2000 anti-hbc igm. These devices are indicated for: immulite. Anti-hbc igm: immulite anti-hbc igm is a solid-phase chemiluminescent enzyme immunoassay designed for use with the immulite automated immunoassay analyzer for the qualitative measurement of igm antibody to hepatitis b core antigen (anti-hbc igm) in human serum and plasma (edta, heparinized or citrate). It is intended for in vitro diagnostic use for the laboratory diagnosis of acute or recent (usually within 6 months) hepatitis b viral infection. Immulite. 2000 anti-hbc igm: immulite 2000 anti-hbc igm is a solid-phase chemiluminescent enzyme immunoassay designed for use with the immulite 2000 automated immunoassay analyzer for the qualitative measurement if igm antibody to hepatitis b core antigen (anti-hbc igm) in human serum and plasma (edta, heparinized or citrate). It is intended for in vitro diagnostic use for the laboratory diagnosis of acute or recent (usually within 6 months) hepatitis b viral infection.

DeviceIMMULITE 2000 XPI ANTI-HBC IMG
Classification NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantSiemens Healthcare Diagnostics Products, LTD
Date Received2001-08-31
Decision Date2002-07-26
Notice Date2003-06-24
PMAP010053
SupplementS
Product CodeLOM
Docket Number03M-0272
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address Siemens Healthcare Diagnostics Products, LTD glyn Rhonwy llanberis, Caernarfon LL55
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P010053Original Filing
S016 2022-09-15 30-day Notice
S015
S014 2022-02-28 30-day Notice
S013 2020-12-22 Real-time Process
S012 2020-08-12 30-day Notice
S011 2019-11-25 30-day Notice
S010 2011-12-19 135 Review Track For 30-day Notice
S009 2011-08-16 30-day Notice
S008 2011-08-08 30-day Notice
S007 2011-02-18 Real-time Process
S006 2009-11-02 Normal 180 Day Track No User Fee
S005
S004 2008-11-10 Normal 180 Day Track No User Fee
S003 2005-08-17 Special (immediate Track)
S002
S001 2002-11-20 Real-time Process

NIH GUDID Devices

Device IDPMASupp
00630414977737 P010053 001
00630414977720 P010053 001
00630414960975 P010053 001

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.